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Supplementary Table 1. Baseline characteristics of CAMERA participants 
Data presented as mean (SD) or n (%) except where indicated (*Geometric mean and 95%CI) 
† calculated using the HOMA2-IR calculator (https://www.dtu.ox.ac.uk/homacalculator/)  
Characteristic Metformin (n=86) Placebo (n=87) 
Males 70 (81%) 63 (72%) 
Age (years) 63 (8) 64 (8) 
Weight (kg) 87.9 (14.1) 86.8 (15.0) 
BMI (kg/m2) 30.2 (4.0) 30.5 (4.4) 
Fasting plasma glucose (mmol/L) 5.4 (0.6) 5.3 (0.5) 
HOMA2-IR*† 1.36 (1.23-1.51) 1.40 (1.25-1.56) 
HbA1c (mmol/mol) 38.7 (3.6) 38.2 (3.3) 
HbA1c (%) 5.6 (0.3) 5.6 (0.3) 
Fasting leptin (ng/mL)* 16.1 (13.6-19.1) 18.7 (15.8-22.1) 
Fasting total GLP-1 (pg/mL)* 11.6 (10.1-13.3) 12.4 (10.9-14.2) 
This is the peer reviewed version of the following article: 'The sustained influence of metformin therapy on 
circulating GLP-1 levels in individuals with and without type 2 diabetes', Diabetes, Obesity & Metabolism which 
has been published in final form at http://dx.doi.org/10.1111/dom.12826. This article may be used for 
noncommercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Supplementary Table 2. Review of previous studies investigating the effect of metformin on circulating GLP-1 
REFERENCE Study summary N, duration Methods Metformin effect on GLP-1 
Kappe et al.  
(2014) 
To determine if high fat diet (HFD) and 
metformin lowers number of entero-endocrine L 
cells and/or GLP-1 plasma levels 
-, - 
 
C57/B16 mice received control/HFD for 12 weeks and 
oral metformin/ saline for last 14 days. ELISA used to 
measure GLP-1 before and after metformin. 
Immunohistochemistry used to quantify GLP-1 positive 
cells in intestinal cells. 
 
- ↓ GLP positive cells in HFD mice 
- improved incretin response 
- intestinal expression of GLP-1R mRNA upregulation 
- improved metformin response in mice on HFD 
Wu et al.  
(2014) 
Study of Caucasian T2DM men treated with 
placebo or metformin to investigate effects on 
DPP-4 and total intact GLP-1 
N=12, 
2 X 7 days 
 
Crossover study with Intra-duodenal glucose infusion 
on day 5 and 8 then C-terminally directed assay and 
sandwich ELISA  
 
- ↓ plasma fasting DPP-4 activity 
- ↑ plasma intact GLP-1 
- no significant difference in total GLP-1 
Solis-Herrera et al. 
(2013) 
Study assessing glucose lowering mechanisms of 
sitagliptin and/or metformin in patients with 
T2DM 
N=16, 
4 X 6 weeks 
Cross-over study with meal tolerance testing, 
radioimmunoassay, glucose oxidase method and ELISA 
 
- ↑ GLP-1 secretion and β cell function in metformin and 
sitagliptin combined (2 to 3 fold ↑ in basal plasma GLP-1 
concentration 
- no significant ↑ with metformin alone 
 
Vardarli et al. 
(2013) 
Effect of metformin, sitagliptin or both on GLP-1 
responses of overweight/obese patients with 
T2DM  
N=20, 
4 X 6 days 
Cross-over study with oral glucose challenge on day 5 
and IV glucose infusion on day 6 then sandwich ELISA 
or C-terminally detected assay 
- metformin ↑ fasting total GLP-1 by ↑ insulin secretory 
responses.  
-Whereas, DPP-4 inhibitor ↑ plasma intact GLP-1 and ↓ total 
GLP-1 
 
Kappe et al. 
(2012) 
Effect of metformin on regulation of GLP-1 
secreting cells -, - 
Used murine GLUTag cell line, 
DNA-fragment assay, ELISA, RT-PCR etc. 
 
- Regulates GLP-1 receptor expression in pancreas 
- Protects GLP-1 cells against lipoapoptosis 
- ↑ secretion of pre-proglucagon 
 
Thondam et al. 
(2012) 
Effect of 3 months of metformin monotherapy on 
GLP-1, ghrelin and DPP-4 in obese T2DM 
patients 
N=8, 
3 months Prospective, observational study using ELISA 
 
-↑ postprandial active GLP-1 levels 
- after 3 months, mean fasting GLP-1 didn’t significantly 
change 
 
Mulherin et al. 
(2011) 
 
Assess direct effects of metformin on GLP-1 
secretion from intestinal L cells and assess 
indirect actions that increase plasma GLP-1. 
 
-, - In vivo and in vitro studies using murine human NCI-H716 and rat FRIC cells 
- ↑ GLP-1 in vivo only (M3 muscarinic dependent effects) 
- activity of DPP-4 not affected 
- ↑ total GLP-1 over 24 hours 
Cuthbertson et al. 
(2011) 
 
Acute effect of metformin and GLP-1 alone or in 
combination on DPP-4 activity in 




Overnight fast then blood tested for DPP-4 activity, 
insulin, GLP-1, glucose and C-peptide concentrations 
using biochemical assays 
- DPP-4 only inhibited by 7% 
- insulin sensitizing effects important in glucose lowering by 
GLP-1 
Maida et al.  
(2011) 
To assess if metformin exerts glucoregulatory 
actions via modulation of the incretin axis using 
knock-out GLP-1R versus obese hyperglycaemic 
wild-type mice with/without exendin 
-, - Assessed incretin receptor expression, glucose tolerance, gastric emptying and food intake 
 
- ↑ GLP-1 levels and improved glucose tolerance in knock-out 
mice. 
- ↑ GLP-1R in INS-1β CELLS via PPAR-α dependent and 
AMPK independent pathways 
 
 
Migoya et al. 
(2010) 
 
Effect of metformin in healthy men and women N=16,  4 X 2 days 
 
Four period (two day) cross-over study including 
placebo and metformin interventions; Day 2 active and 
total GLP-1 and GIP and glucose plasma concentrations 
measured pre-meal and post-meal 
 
- ↑ postprandial total GLP-1 concentrations in plasma 
- ↑ postprandial active GLP-1 concentrations  
- no effect on total or active GIP concentrations 
- no effect on postprandial DPP-4 activity  
Svendsen et al.  
(2009) 








Uncontrolled interventional study with 180min oral 
glucose loading tests and comparison to baseline 
 
- ↑ area under GLP-1 curve  
Green et al.  
(2006) 
Effect of metformin on DPP-4 activity in normal 
and obese diabetic mice  -, - 
 
Radioimmunoassay using blood samples taken 30 
minutes post-intraperitoneal injection of glucose and 
GLP-1 or GLP-1+ metformin 
 
- in vivo metformin ↓ DPP-4 activity in ob/ob mice with 
improved glucose lowering and insulin release from GLP-1 
-  ↑ circulating GLP-1 (7-36) amide levels 
Mannucci et al. 
(2004) 
Effect of metformin on 22 obese T2DM versus 




GLP-1 measured before and after 100g glucose load 
after 4 weeks of 850mg metformin 
 
- Single dose didn’t modify GLP-1 
- fasting GLP-1 ↑ after 4 weeks of metformin  
Hinke et al.   
(2002) 
Investigates whether metformin acts as a DPP-4 




In vitro analysis of 20% human serum, porcine kidney 
and recombinant human DPP-4 using mass 
spectrometry and surface plasmon resonance 
 
- Metformin does not act directly on DPP-4  
- Instead, it may ↑ GLP-1 and glucagon secretion from 
pancreatic α cells and intestinal L cells  
Mannucci et al.  
(2001) 
Effect of metformin versus placebo on GLP-1 
and leptin in obese non-diabetic men before and 




GLP-1 measured using ELISA in fasting state and after 
oral glycaemic load during euglycaemic 
hyperinsulinaemic clamp 
 
- significant GLP-1 ↑ at 30 and 60 minutes after oral glucose 
load 
-no GLP-1 variation in controls 
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